Edition:
United States

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

4.07USD
28 Apr 2017
Change (% chg)

$-0.24 (-5.57%)
Prev Close
$4.31
Open
$4.28
Day's High
$4.33
Day's Low
$4.05
Volume
30,071
Avg. Vol
51,159
52-wk High
$4.68
52-wk Low
$1.66

Latest Key Developments (Source: Significant Developments)

Imprimis Pharmaceuticals and Precision Lens sign agreement
Tuesday, 18 Apr 2017 08:30am EDT 

April 18 (Reuters) - Imprimis Pharmaceuticals Inc :Imprimis Pharmaceuticals and Precision Lens sign agreement to expand Imprimis' ophthalmic portfolio market opportunity in the U.S. Midwest.Imprimis Pharmaceuticals - under deal, Precision Lens will deploy sales team to introduce Imprimis' ophthalmic portfolio into select geographies in U.S..  Full Article

Imprimis Pharmaceuticals says entered sales & marketing agreement
Monday, 17 Apr 2017 04:48pm EDT 

April 17 (Reuters) - Imprimis Pharmaceuticals Inc ::Imprimis Pharmaceuticals Inc - on april 13, co entered into a strategic sales & marketing agreement with Cameron Ehlen Group, Inc. DBA Precision Lens.Imprimis Pharmaceuticals-pursuant to agreement,precision lens to provide exclusive sales,marketing services to co in select geographies in U.S. Midwest.Imprimis Pharmaceuticals-under terms of agreement,co to make commission payments, certain periodic milestone payments to precision lens- sec filing.  Full Article

Imprimis Pharmaceuticals acquires license to patented formulation for dry eye disease
Thursday, 6 Apr 2017 08:30am EDT 

Imprimis Pharmaceuticals Inc - : Imprimis Pharmaceuticals acquires exclusive license to patented ophthalmic formulation for dry eye disease . Imprimis Pharmaceuticals - under terms of agreement, imprimis will pay lindstrom an upfront fee, milestone payments, and royalty payments on product sales .Imprimis Pharmaceuticals- under terms of agreement, imprimis will pay lindstrom upfront fee, milestone payments, royalty payments on product sales.  Full Article

Longboard Capital Advisors reports 6.58 pct passive stake in Imprimis Pharmaceuticals
Wednesday, 29 Mar 2017 06:11am EDT 

Imprimis Pharmaceuticals Inc :Longboard Capital Advisors reports 6.58 percent passive stake in Imprimis Pharmaceuticals Inc as on March 21, 2017.  Full Article

Imprimis Pharmaceuticals implemented an expense reduction program
Monday, 26 Sep 2016 08:30am EDT 

Imprimis Pharmaceuticals Inc : Co implemented an expense reduction program . Has ceased operations at its Texas facility and implemented an 8% reduction in total headcount . Exploring alternatives for use of Texas facility, estimates will incur total restructuring costs of about $0.6 million under plan .Actions are expected to streamline Imprimis' operations and reduce expected cash based expenses by nearly $3 million annually.  Full Article

Imprimis Pharmaceuticals Q2 revenue $4.9 million
Monday, 15 Aug 2016 04:03pm EDT 

Imprimis Pharmaceuticals Inc : Imprimis pharmaceuticals announces second quarter 2016 financial results . Q2 revenue rose 150 percent to $4.9 million .Qtrly net loss per common share $0.35.  Full Article

Imprimis Pharmaceuticals $2 mln sale agreement with Essex Capital
Thursday, 11 Aug 2016 08:30am EDT 

Imprimis Pharmaceuticals Inc : Agreement covers sale and leaseback of Imprimis' drug manufacturing equipment and has an initial term of up to three years . Agreement covers an additional one-year lease extension, subject to Imprimis achieving certain financial milestones .Imprimis Pharmaceuticals announces $2 million equipment sale leaseback agreement with Essex Capital Corporation.  Full Article

Imprimis Pharmaceuticals Q1 loss per share $0.43
Thursday, 12 May 2016 04:10pm EDT 

Imprimis Pharmaceuticals Inc : Q1 loss per share $0.43 . Imprimis pharmaceuticals announces first quarter 2016 financial results and provides business update .Q1 revenue $4.4 million versus $1.6 million.  Full Article

Imprimis Pharmaceuticals, Inc announces pricing of public offering of common stock
Friday, 11 Mar 2016 08:45am EST 

Imprimis Pharmaceuticals, Inc:Pricing of an underwritten public offering of 2.9 million shares of its common stock at a price to the public of $3.60 per share, before underwriting discounts.Offering is expected to close on or about March 16, 2016, subject to satisfaction of customary closing conditions.  Full Article

Imprimis Pharmaceuticals Inc reaffirms FY 2015 revenue guidance
Thursday, 12 Nov 2015 04:03pm EST 

Imprimis Pharmaceuticals Inc:Projects total revenue for FY 2015 to be approximately $9 - $11 million.  Full Article

More From Around the Web

BRIEF-Imprimis Pharmaceuticals and Precision Lens sign agreement

* Imprimis Pharmaceuticals and Precision Lens sign agreement to expand Imprimis' ophthalmic portfolio market opportunity in the U.S. Midwest